Results 101 to 110 of about 2,198,265 (159)

ATTR-CM, HFpEF, and Clinical Cardiology: It Is Not a Moment, It Is a Movement. [PDF]

JACC CardioOncol, 2021
Nayak GS.
europepmc   +1 more source

Total atrial conduction time predicts new-onset atrial fibrillation in patients with transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy resulting from age-related failure of homoeostatic mechanisms in wild-type ATTR (wtATTR-CM) or destabilizing mutations in variant TTR (vATTR-CM). Atrial fibrillation (AF) is
Melpignano, Angelo, Fabbri, Gioele, Campo, Gianluca, Izzo, Carmen, Serenelli, Matteo, Guidi Colombi, Gabriele, Bertini, Matteo, Arzenton, Matteo, Cantone, Anna, Dal Passo, Beatrice, Pavasini, Rita, Marchini, Federico, Bonini, Jacopo   +12 more
core   +1 more source

Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus. [PDF]

Indian Heart J, 2022
Chander Mohan J, Dalal J, Chopra VK, Narasimhan C, Kerkar P, Oomman A, Ray Fcsi S, Sharma AR, Dougall P, Simon S, Verma Drm A, Radhakrishnan V.   +11 more
europepmc   +1 more source

Identifying Suspected ATTR-CM From Unstructured EHR Data Using AI. [PDF]

JACC Adv
Batinica B, Cheng RK, Khera R.
europepmc   +1 more source

The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM. [PDF]

JACC CardioOncol
Witteles RM.
europepmc   +1 more source

ATTR-CM in Patients With Clinically Significant Plasma Cell Dyscrasias: A Case Series Highlighting Diagnostic Challenges. [PDF]

JACC Case Rep
Ancha B, Brown E, Ranek M, Lollo N, Huff CA, Ali SA, Gocke CB, Imus P, Brookmeyer C, Steenbergen C, Polydefkis M, Vaishnav J.   +11 more
europepmc   +1 more source

Patient Perspectives on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Attributes. [PDF]

Cardiol Ther
Kumar N, Coulter J, Haddad-Angulo A, Baig L, Chung H, Chandrasekar SM, Vass C, Galinsky J, Carr AM, McIntosh K, Hauber B.   +10 more
europepmc   +1 more source

Diagnostic pathway for cardiac amyloidosis from the healthcare professional’s perspective: results from the French DIAM-ATTR survey

Background Diagnosis of cardiac amyloidosis (CA) is complex and implicates several medical specialists. CA is usually suspected based on symptoms (‘red flags’) and non-invasive imagery.
Charron, Philippe, Damien Legallois, Legallois, Damien, Bardin, Thomas, Sauvage, Cédric, Cédric Sauvage, Fournier, Pauline, Oghina, Silvia, Benoit Bouquillon, Pierre Sabouret, Thomas Bardin, Bouquillon, Benoit, Emmanuel Andrès, Andrès, Emmanuel, Damy, Thibaud, Piriou, Nicolas, Tresorier, Romain, Hyafil, Fabien, Olivier Toulza, Walid Amara, Pauline Fournier, Amara, Walid, Dubois, Margaux, Giorgia Canali, Céline Labeyrie, Romain Tresorier, Fabien Hyafil, Guignard, Sandra, Sabouret, Pierre, Sandra Guignard, Thibaud Damy, Toulza, Olivier, Labeyrie, Céline, Silvia Oghina, Canali, Giorgia, Nicolas Piriou, Philippe Charron, Margaux Dubois   +37 more
core   +1 more source

Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Methven Jeknić S, Ahn-Horst TA, Ji AX, Ju JH, Paull M, Ji SG, Sinha U.   +6 more
europepmc   +1 more source

The First Korean Clinical Evidence With Tafamidis in ATTR-CM. [PDF]

Korean Circ J
Lee J, Oh J.
europepmc   +1 more source